Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Propanc Biopharma, Inc. Common Stock

PPCB

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $1.76 – $2.05
Volume 4,096
Market cap $2M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.86M
Price / earnings
—
Price / book
0.26×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.08×

Profitability

Earnings per share
-$23.95
Return on assets
-228%
Return on equity
-333.05%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.02×
Current ratio
2.47×
Quick ratio
2.47×
Cash ratio
0.08×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$5.72M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PPCB, quarterly periods
Line itemQ1 FY2027 Sep 30, 2026Q4 FY2026 Jun 30, 2026Q3 FY2026 Mar 31, 2026Q2 FY2026 Dec 31, 2025Q1 FY2026 Sep 30, 2025
Revenue$0$0$0$0$0
Cost of revenue$0$0$0$0$0
Gross profit$0$0$0$0$0
Selling, general and administrative$2.44M$3.08M$6.23M$3.63M$262.13K
Research and development$457.68K$375.66K$169.66K$19.96K$60.2K
Total operating expenses$8.57M$3.46M$6.4M$3.65M$4.67M
Operating income-$8.57M-$3.46M-$6.4M-$3.65M-$4.67M
Interest expense-$18.24K-$27.67K-$38.27K-$58.96K-$305.65K
Income before taxes-$8.59M-$4.57M-$6.36M-$3.09M-$4.84M
Income taxes$0$0$0$0$0
Net income-$8.59M-$4.57M-$6.36M-$3.09M-$4.84M
Net income attributable to common shareholders-$8.59M-$4.57M-$6.36M-$4.02M-$4.84M
EBITDA-$8.57M-$3.46M-$6.4M-$3.65M-$4.67M
Basic earnings per share-$12.22-$17.79-$70.00-$75.00-$98.08
Diluted earnings per share-$12.22-$17.79-$70.00-$75.00-$98.08

Recent news

Company coverage with links to the original publishers.

Publication times in UTC

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 26, 20261-for-10reverse split
May 18, 20261-for-25reverse split
Jan 29, 20251-for-60,000reverse split
May 23, 20231-for-1,000reverse split
Nov 19, 20201-for-1,000reverse split
Jun 24, 20191-for-500reverse split